# Mirugen, Pty.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mirugen-pty

- Industry: Biotechnology
- Headquarters: Melbourne, Australia
- Website: www.mirugen.com/
- Total disclosed funding: $2.9M
- Latest round: Seed (Aug 13, 2025)
- Investors on record: 4

## About

Founded in 2022 and headquartered in Melbourne, Australia, Mirugen, Pty. Ltd. specializes in cell reprogramming therapies. In August 2025, Mirugen, Pty. Ltd. raised AUD 4.5 million in seed funding from new investors CUREator, Brandon Capital Partners, Tin Alley Ventures, and Tanarra Capital, with participation from other unspecified investors. Mirugen operates at the forefront of cell reprogramming to address significant health challenges associated with blindness. The company's primary focus is on leveraging its discovery platform, which integrates sequencing data, bioinformatics, and high-throughput screening, to identify key transcription factors that facilitate the conversion of one cell type into another. Their pioneering approach targets Muller Glial cells in the eye, aiming to regenerate lost photoreceptors, which are essential for vision. This innovative technology primarily addresses Retinitis Pigmentosa, affecting approximately 1.5 million individuals globally, with potential applications extending to other prevalent eye diseases such as Age-related Macular Degeneration and Stargardt’s disease. Currently, Mirugen's products and services are geared towards clinical research institutions and biotech companies within the healthcare sectors of North America, Europe, and parts of Asia, where the demand for advanced gene therapy solutions is rapidly growing.Mirugen's revenue model is structured around partnerships and collaborations with clinical research organizations, academic institutions, and potentially commercial pharmaceutical companies engaged in gene therapy and regenerative medicine. Transactions typically occur through direct collaboration agreements, which may involve milestone-based payments tied to research and development progress, as well as potential licensing of proprietary technologies for commercial use. While specific pricing plans for their services are not disclosed, it can be anticipated that such transactions will align with industry standards, involving negotiated fees based on the scope and scale of the projects. The firm’s flagship offerings center around its innovative cell reprogramming technologies, designed to harness cellular repair mechanisms, with an emphasis on advancing therapeutic solutions for eye diseases.In August 2025, Mirugen, Pty. Ltd. raised an undisclosed amount of venture funding from unspecified investors. The company will utilize this funding to advance its retinal pigment epithelium cell reprogramming therapy targeting retinal disease. Future growth initiatives include the development of new products aimed at enhancing therapeutic solutions for retinal diseases, with specific release dates to be determined. Additionally, Mirugen plans to expand its market presence into new geographic regions, including Asia and Europe, by the end of 2026.

## Funding rounds

- Seed, Aug 13, 2025, $2.9M — Tanarra Capital, Brandon Capital Partners, CUREator, Tin Alley Ventures

## Investors

- Tanarra Capital (https://capitalatlas.ai/funds/tanarra-capital) — Seed
- Brandon Capital Partners (https://capitalatlas.ai/funds/brandon-capital-partners) — Seed
- CUREator — Seed
- Tin Alley Ventures — Seed